Skip to main content
SpringerPlus

Table 3 Adverse events

From: Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone

 

Mitoxantrone (n=186)

CMFP (n=191)

 
 

Any grade

Grade 3–4

Any grade

Grade 3–4

 

Adverse event

N

N

n

n

P *

Hematuria

4

0

6

0

0.75

Stomatitis

34

2

91

21

<0.001

Nausea and vomiting

135

10

137

9

0.82

Alopecia

83

0

131

0

<0.001

Diarrhea

19

0

56

2

<0.001

Somnolence

14

0

34

2

0.003

Anemia

83

5

119

15

0.001

Leukopenia

138

56

146

60

0.64

Neutropenia

114

52

109

53

0.29

Thrombocytopenia

23

10

35

15

0.12

Other

68

4

111

30

<0.001

  1. * P for any adverse event vs none between the two treatment groups.
  2. CMFP, combination therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.
Back to article page